Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 20Colorectal Neoplasms 17Neoplasm Metastasis 17Lymphoma, Non-Hodgkin 15Ovarian Neoplasms 15Carcinoma, Renal Cell 14Leukemia 14Leukemia, Lymphocytic, Chronic, B-Cell 14Melanoma 14Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lung Neoplasms 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 11Carcinoma, Hepatocellular 10Hematologic Neoplasms 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Adenocarcinoma 9Glioma 9Lymphoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 9Prostatic Neoplasms 9Stomach Neoplasms 9

Interventions

Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Myelomonocytic, Juvenile × Clear all
NCT02447666 2019-07-11

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Celgene

Phase 2 Completed
28 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡